Medical condition
Hypertension
Hypertension is a medical condition tracked by NovaPharmaNews across 12 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- sildenafil (NOUMED SILDENAFIL) Genito-urinary system and sex hormones (G04)
- azilsartan medoxomil (EDARBI) Cardiovascular system (C09)
- dabigatran etexilate (DABIGATRAN ETEXILATE ACCORD) Blood and blood forming organs (B01)
- aliskiren (RASILEZ) Cardiovascular system (C09)
- riociguat (ADEMPAS) Cardiovascular system (C02)
- bosentan (BOSENTAN APO) Cardiovascular system (C02)
- liraglutide (SAXENDA) Alimentary tract and metabolism (A10)
- naltrexone (ARX-NALTREXONE) Alimentary tract and metabolism (A08)
- irbesartan (ABISART 150) Cardiovascular system (C09)
- apixaban (ELIQUIS) Blood and blood forming organs (B01)
- bimatoprost (BIMATOPROST SANDOZ) Sensory organs (S01)
- rivaroxaban (APO-RIVAROXABAN) Blood and blood forming organs (B01)
Latest Hypertension news
FDA Approves AstraZeneca’s Baxdrostat for Hypertension
The FDA has approved AstraZeneca's baxdrostat for treating hypertension, marking a significant milestone in hypertension management. This article explores the implications for pharmaceutical stakeholders.
AstraZeneca Secures FDA Approval for Hypertension Drug
AstraZeneca has gained FDA approval for its new hypertension drug, marking a significant milestone in the pharmaceutical industry. This approval opens new avenues for investment and competition.
FDA Approves AstraZeneca's Innovative Hypertension Drug
AstraZeneca's innovative hypertension drug has received FDA approval, marking a significant milestone in hypertension treatment. This article explores the implications for the pharmaceutical industry.
Pulnovo Medical Secures $100 Million Investment from Medtronic for Pulmonary Hypertension Therapies
Pulnovo Medical raises $100M in oversubscribed funding led by Medtronic to advance breakthrough pulmonary hypertension and heart failure treatments.
FDA Approves Verapamil: Cardio-Med’s Extended-Release Formulation for Hypertension
The FDA has approved Cardio-Med’s extended-release formulation of Verapamil, offering a new option for managing hypertension effectively.
FDA Approves LungRx Inhaled Therapy: Breakthrough for Pulmonary Hypertension
The FDA has granted approval for LungRx, an inhaled therapy that offers a groundbreaking treatment for pulmonary hypertension, enhancing patient care and outcomes.